Full year 2022 commercial revenue expected to be between
Finished 2022 with approximately
Company to Present at the 41st Annual
Select Fourth Quarter 2022 Highlights and Preliminary Unaudited Revenue
- Placed two Growth Direct systems and completed the validation of three systems
- Added new global Top 20 pharma customer in the
U.S. and new large pharma customer inJapan - Launched RMBNucleus™ Mold Alarm software
The Company currently expects total commercial revenue of between
Preliminary Unaudited Full Year 2022 Revenue
The Company currently expects total commercial revenue of between
The preliminary financial results ranges described herein have not been audited and are subject to adjustment based on the Company’s completion of year-end financial close processes.
The Company plans to announce complete financial results for the fourth quarter and full year 2022 and host a webcast to discuss those results as well as its 2023 outlook in March.
Presentation at
The Company is scheduled to present at the 41st Annual
About
For more information, please visit www.rapidmicrobio.com or follow the Company on Twitter at @rapidmicrobio or on LinkedIn.
Forward-Looking Statements
This press release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including, but not limited to, statements relating to guidance on financial results for the fourth fiscal quarter and full year 2022; expectations regarding the Company’s preliminary commercial revenue outlook for the full year 2023; the Company’s expectations for future revenue and growth; acceleration of growth initiatives; expectations for the RMBNucleus™ Mold Alarm; expectations regarding the Company’s improvements in commercial execution and enhanced sales and marketing processes; and customer interest in and adoption of the Company's Growth Direct microbial quality control platform.
In some cases, you can identify forward-looking statements by terminology such as “outlook,” “aim,” “anticipate,” “assume,” “believe,” “contemplate,” “continue,” “could,” “due,” “estimate,” “expect,” “goal,” “intend,” “may,” “objective,” “plan,” “predict,” “potential,” “positioned,” “seek,” “should,” “target,” “will,” “would” and other similar expressions that are predictions of or indicate future events and future trends, or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words. Forward-looking statements involve known and unknown risks, uncertainties and assumptions which may cause actual results to differ materially from any results expressed or implied by any forward-looking statement, including, but not limited to, the impact of macroeconomic volatility and COVID-19 and its variants on the Company’s business and operations, including further delays in placements and validation of new systems; our significant losses since inception; the Company’s ability to meet its publicly announced guidance and other expectations about its business and operating results; the Company’s ability to manage our future growth effectively; our limited experience in marketing and sales and the effectiveness of its sales processes; the Company’s need to develop new products and adapt to technological changes; the Company’s ability to establish and maintain its position as a leading provider of automated microbial quality control testing; the Company’s ability to maintain its manufacturing facilities; risks related to third-parties; the Company’s ability to retain key management and other employees; risks related to regulatory and intellectual property matters; risks related to supply chain disruptions and the impact of inflation; and the other important factors outlined under the caption “Risk Factors” in the Company’s Annual Report on Form 10-K, filed with the
![](https://ml.globenewswire.com/media/NmMwYjQ4OGQtYzg1ZS00MDZlLTg1YjEtZjE5YzA3NTZhNjlhLTEwMzAxMzQ=/tiny/Rapid-Micro-Biosystems-Inc-.png)
Investor Contact:Michael Beaulieu , CFA Vice President, Investor Relations and Corporate Communications mbeaulieu@rapidmicrobio.com Media Contact: media@rapidmicrobio.com
2023 GlobeNewswire, Inc., source